Abbott Laboratories Launches Oncodetect Molecular Residual Disease Test

MT newswire2026/10/26 13:49

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

09:49 AM EDT, 10/26/2026 (MT Newswires) -- Abbott Laboratories (ABT) has commercially launched the Oncodetect molecular residual disease, or MRD, test, the company said Monday. The personalized test is designed to deliver molecular insights during and after cancer treatment, using the patient's tumor sample to identify unique DNA markers, Abbott said. Oncodetect is backed by whole-genome sequencing and the MAESTRO technology to expand variant discovery, the company added. The test is available for patients with solid tumors but has not been cleared or approved by the US Food and Drug Administration. Price: 104.03, Change: +0.33, Percent Change: +0.32

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.

华尔街见闻•2026/11/07 07:31